The FSP1-CoQ10 pathway was first identified in a 2019 study by K. Bersuker et al., who observed substantial variability in the sensitivity of various cancer cell lines to GPX4 inhibitors (Bersuker et al., 2019). Here, GPX4 is linked to cancer.